Trial · NCT03471871
Participant flow95
How many started, completed or left each group, period by period.
1 to 20 of 95
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period 1(HV:1 Day, OSA:8 Days) | STARTED | HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg | 6 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | STARTED | HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo | 5 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | STARTED | HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg | 6 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | STARTED | OSA Cohort, Sequence D: Placebo, Lemborexant 10mg | 19 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | STARTED | OSA Cohort, Sequence E: Lemborexant 10mg, Placebo | 20 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | Treated | HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg | 6 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | Treated | HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo | 5 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | Treated | HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg | 6 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | Treated | OSA Cohort, Sequence D: Placebo, Lemborexant 10mg | 18 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | Treated | OSA Cohort, Sequence E: Lemborexant 10mg, Placebo | 20 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | COMPLETED | HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg | 6 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | COMPLETED | HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo | 5 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | COMPLETED | HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg | 5 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | COMPLETED | OSA Cohort, Sequence D: Placebo, Lemborexant 10mg | 18 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | COMPLETED | OSA Cohort, Sequence E: Lemborexant 10mg, Placebo | 19 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | NOT COMPLETED | HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg | 0 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | NOT COMPLETED | HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo | 0 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | NOT COMPLETED | HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg | 1 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | NOT COMPLETED | OSA Cohort, Sequence D: Placebo, Lemborexant 10mg | 1 | |
| Treatment Period 1(HV:1 Day, OSA:8 Days) | NOT COMPLETED | OSA Cohort, Sequence E: Lemborexant 10mg, Placebo | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03471871/flow